What is HC Wainwright’s Estimate for CNTX Q3 Earnings?

Context Therapeutics Inc. (NASDAQ:CNTX) – HC Wainwright issued their Q3 2025 earnings per share (EPS) estimates for Context Therapeutics in a report issued on Friday, March 21st. HC Wainwright analyst E. Bodnar forecasts that the company will post earnings of ($0.05) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $5.00 target price on the stock. The consensus estimate for Context Therapeutics’ current full-year earnings is ($0.51) per share. HC Wainwright also issued estimates for Context Therapeutics’ Q4 2025 earnings at ($0.05) EPS.

Several other research firms have also issued reports on CNTX. D. Boral Capital restated a “buy” rating and issued a $9.00 price target on shares of Context Therapeutics in a research report on Friday. Citizens Jmp raised Context Therapeutics to a “strong-buy” rating in a research report on Wednesday, January 8th. Finally, JMP Securities began coverage on Context Therapeutics in a research note on Wednesday, January 8th. They set an “outperform” rating and a $4.00 price target on the stock. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $6.17.

Context Therapeutics Trading Down 1.0 %

Shares of Context Therapeutics stock opened at $0.76 on Monday. The company has a market cap of $57.30 million, a price-to-earnings ratio of -0.84 and a beta of 2.06. Context Therapeutics has a 1 year low of $0.64 and a 1 year high of $2.75. The company’s fifty day simple moving average is $0.85 and its 200-day simple moving average is $1.42.

Context Therapeutics (NASDAQ:CNTX) last issued its quarterly earnings results on Thursday, March 20th. The company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.05) by $0.01.

Institutional Trading of Context Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. State Street Corp lifted its stake in Context Therapeutics by 21.5% during the third quarter. State Street Corp now owns 111,907 shares of the company’s stock worth $219,000 after purchasing an additional 19,800 shares during the period. Y Intercept Hong Kong Ltd acquired a new position in shares of Context Therapeutics in the 3rd quarter worth approximately $89,000. Franklin Resources Inc. bought a new position in shares of Context Therapeutics during the 3rd quarter worth approximately $3,689,000. Clear Harbor Asset Management LLC boosted its stake in Context Therapeutics by 60.6% in the 4th quarter. Clear Harbor Asset Management LLC now owns 57,804 shares of the company’s stock valued at $61,000 after buying an additional 21,804 shares in the last quarter. Finally, Geode Capital Management LLC grew its position in Context Therapeutics by 9.2% in the fourth quarter. Geode Capital Management LLC now owns 628,729 shares of the company’s stock valued at $661,000 after acquiring an additional 52,830 shares during the period. Institutional investors own 14.03% of the company’s stock.

Context Therapeutics Company Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.